5-Amino-1MQ

A selective, cell-permeable inhibitor of NNMT, studied for fat metabolism, lean-mass preservation, and intracellular NAD+ support via SIRT1 activation.

Profile · 01

Overview

5-Amino-1MQ is a selective, cell-permeable inhibitor of nicotinamide N-methyltransferase (NNMT), studied for its potential to support fat metabolism, preserve lean muscle mass, and elevate intracellular NAD+ levels by blocking NNMT and activating SIRT1 pathways. It is not FDA-approved for any indication.

Preclinical models demonstrate reductions in fat mass and improvements in metabolic markers, though human clinical data remain limited to early investigational work. This protocol presents a once- or twice-daily subcutaneous approach using practical dilution for clear insulin-syringe measurements.

At a Glance

Goal
Support fat metabolism, preserve lean muscle mass, and elevate NAD+ levels
Categories
Fat LossMetabolic SupportNAD+ EnhancementBody Composition
Synergistic
NMN (Nicotinamide Mononucleotide) · NR (Nicotinamide Riboside) · AOD-9604
Profile · 02

Protocol

Tolerance assessment followed by standard daily dosing; twice-daily option for sustained NNMT inhibition.

Typical daily range
2.5–5 mg once or twice daily (subcutaneous)
Start
2.5 mg once daily for Days 1–2 (tolerance assessment)
Target
5 mg once daily from Day 3 onward; optional 2.5 mg BID split
Frequency
Once or twice per day (subcutaneous)
Cycle Length
4–8 weeks; plan multiple vials for extended protocols
Timing
Any consistent time; if BID, split AM/PM; rotate injection sites
Route
Subcutaneous
Cycle
4–8 weeks on, 4 weeks off

Inject once or twice daily subcutaneously. Due to the compound's plasma half-life of approximately 3.8–6.9 hours, twice-daily dosing may provide more sustained NNMT inhibition. At standard doses, a single vial provides only a few days of material, so plan multiple vials for extended protocols. Dosing extrapolates from preclinical models; human clinical validation remains limited.

Dose progression

Days 1–2
2.5 mg (2500 mcg)
Days 3+
5 mg (5000 mcg)
Alt. BID
2.5 mg × 2 (5000 mcg total)

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Profile · 03

Videos

Science · 01

How 5-Amino-1MQ works.

5-Amino-1MQ selectively inhibits NNMT, a cytosolic enzyme that methylates nicotinamide using S-adenosylmethionine (SAM) as a methyl donor. In obesity and metabolic dysfunction, NNMT is overexpressed in adipose tissue, depleting nicotinamide and reducing NAD+ availability.

By inhibiting NNMT, 5-Amino-1MQ spares nicotinamide for NAD+ synthesis via the salvage pathway, activating SIRT1 pathways associated with mitochondrial biogenesis, fat oxidation, and metabolic flexibility. Preclinical studies have demonstrated reductions in body weight and fat mass without affecting food intake, along with preserved or improved lean muscle mass. However, large-scale controlled human efficacy data remain unavailable.

Science · 02

Effects

Observations from clinical or preclinical literature.

May support reductions in fat mass while preserving lean muscle in animal models (preclinical data)
Associated with elevated NAD+ levels and SIRT1 activation in preclinical settings
Enhanced grip strength observed in aged mice when combined with exercise (animal data)
Generally well tolerated in preclinical studies at tested doses
Occasional mild headache, transient jitteriness, or injection-site reactions may occur
Mild stinging sensation possible due to quinolinium structure
Long-term human safety and efficacy remain under investigation
Science · 03

Caution

Not recommended during pregnancy or breastfeeding (no safety data available)
Use with caution if taking medications that affect NAD+ metabolism or methylation pathways
Individuals with active cancer should consult an oncologist before use due to potential metabolic pathway modulation
Consult a healthcare provider before use if you have any chronic medical conditions

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Lifestyle · 01

CoFactors

NMN or NR
Complementary NAD+ precursors that may synergize with NNMT inhibition to boost intracellular NAD+ levels.
B Vitamins (B3, B6, B12)
Support methylation and NAD+ metabolism pathways.
Magnesium
Supports enzymatic processes involved in energy metabolism and mitochondrial function.
Omega-3 fatty acids
Support anti-inflammatory pathways and metabolic health.
Lifestyle · 02

Life Factors

Complementary strategies for best outcomes.

Pair with balanced, protein-forward diet tailored to energy needs to support body composition goals
Combine resistance training and aerobic activity to amplify metabolic adaptations (preclinical synergy with exercise noted)
Prioritize sleep and stress management for optimal metabolic adaptation and recovery
Consider complementary NAD+ precursors (NMN/NR) per emerging stack protocols
Lifestyle · 03

Metrics

Day-to-day metrics worth tracking through the protocol.

  1. Body composition (weight, waist circumference, body fat %) — monitor changes to gauge metabolic response
  2. Energy levels and exercise performance — track daily to identify improvements in endurance and recovery
  3. Injection-site reactions — note any redness, stinging, or discomfort to guide site rotation
  4. Subjective well-being and appetite — monitor for any unexpected changes during the protocol
Lifestyle · 04

Labs

Baseline and periodic bloodwork to monitor systemic health during the protocol.

Fasting glucose and HbA1c
Assess metabolic function and insulin sensitivity before and during protocol.
Lipid panel
Monitor cholesterol and triglyceride levels for metabolic improvements.
CMP (Comprehensive Metabolic Panel)
Assess liver and kidney function during peptide use.
CBC (Complete Blood Count)
Monitor overall health and rule out underlying conditions.
Calculators · 01

Supplies Calculator

Estimates assume the schedule defined for this peptide.

Length
Vial size
Bac. water
Syringe
Vials
0 × 10 mg each…
Syringes
0
Bac. water
0 mL
Swabs
02 per syringe
Calculators · 02

Dose Calculator

Dose Calculator

Vial
Bac. water
Syringe
Dose
Concentration
0mg/mL
Volume per dose
0mL
…
Practice · 01

Preparation

Careful technique preserves potency. Solution should be clear — do not shake.

  1. Allow vial to reach room temperature for 15–20 minutes before reconstitution.
  2. Draw the chosen bacteriostatic water volume with a sterile syringe.
  3. Inject slowly down vial wall; avoid foaming.
  4. Gently swirl/roll until dissolved (do not shake).
  5. Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
  6. Use within 30 days; discard any unused solution after 30 days.
Practice · 02

Technique

General subcutaneous guidance from clinical best-practice resources.

Clean vial stopper and skin with alcohol; allow to dry
Pinch a skinfold; insert needle at 45–90° into subcutaneous tissue
Do not aspirate for subcutaneous injections; inject slowly and steadily
Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy
Discard used syringes immediately in sharps container per WHO guidelines

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Practice · 03

Storage

Lyophilized
Store at room temp in dry, dark conditions; minimize moisture exposure.
Reconstituted
Refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles. Discard reconstituted vials after 30 days.

Notes

Allow vials to reach room temperature before opening to reduce condensation uptake.
Reference · 01

Notes

Use new sterile insulin syringes for each injection; dispose in sharps container
Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation
Inject slowly; a mild stinging sensation may occur due to the quinolinium structure
Document daily dose and site rotation to maintain consistency
Multiple vials required for extended protocols at standard doses; plan supply accordingly
5-Amino-1MQ human data are preliminary; clinical decisions should involve qualified healthcare providers
Reference · 02

References

  1. Nature Medicine (2014)
    Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high-fat-diet-induced obesity in mice — Neelakantan H et al.
    https://www.nature.com/articles/nm.3702
  2. PMC (2024)
    NNMT inhibition and NAD+ metabolism: mechanisms and therapeutic implications.
    https://pmc.ncbi.nlm.nih.gov/
  3. Frontiers in Pharmacology (2024)
    5-Amino-1MQ and NNMT inhibition: pharmacological review and metabolic applications.
    https://www.frontiersin.org/journals/pharmacology
  4. PubMed (2021)
    NNMT as a therapeutic target in metabolic disease and obesity.
    https://pubmed.ncbi.nlm.nih.gov/
  5. Creative Peptides
    5-Amino-1MQ product information and technical specifications.
    https://www.creative-peptides.com/
  6. CDC
    Vaccine administration: subcutaneous route (angle/site; no aspiration).
    https://www.cdc.gov/vaccines/hcp/admin/downloads/YCTS-VaxAdmin-Subcut-injection.pdf
  7. WHO (NCBI Bookshelf, 2016)
    Guideline on safety-engineered syringes for IM, ID, and SC injections in health care settings.
    https://www.ncbi.nlm.nih.gov/books/NBK390474/
  8. PMC
    Subcutaneous Drug Injection Review — pharmacologic considerations of the subcutaneous route.
    https://pmc.ncbi.nlm.nih.gov/articles/PMC6822791/
On this page